Anti-spasticity medications

Saudi Medical Journal

Volumn 24, Issue 1, 2003, Pages 19-22

  Al Shahrani, Abdulrahman M ^a  

^a IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMINOGLYCOSIDE; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; ANXIOLYTIC AGENT; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN; CLONIDINE; CYPROHEPTADINE; DANTROLENE; DEXTROMETHORPHAN; DIAZEPAM; DRUG METABOLITE; GABAPENTIN; MORPHINE; OXAZEPAM; PHENOTHIAZINE DERIVATIVE; SEDATIVE AGENT; SPASMOLYTIC AGENT; TIZANIDINE; VALPROIC ACID; VIGABATRIN;

ASTHENIA; ATAXIA; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COMPLICATION; DISABILITY; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG USE; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; HALLUCINATION; HUMAN; HYPOTENSION; LIVER TOXICITY; MORBIDITY; PATIENT CARE; PHYSICIAN; PRACTICE GUIDELINE; RESPIRATION DEPRESSION; REVIEW; SEDATION; SPASTICITY; TREATMENT INDICATION; VERTIGO; XEROSTOMIA;

BACLOFEN; BENZODIAZEPINES; BOTULINUM TOXIN TYPE A; CLONIDINE; HUMANS; MUSCLE RELAXANTS, CENTRAL; MUSCLE SPASTICITY; PARASYMPATHOLYTICS;

EID: 0037228633     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Young RR. Spasticity: a review. Neurology 1994; 44 Suppl 9: S12-20.
2. Gelber DA, Jozefezyk PB. Therapeutics in the management of spasticity. Neurorehabilitation and Neural Repair 1999; 13: 5-14.
3. Gelber DA, Jozefezyk PB. Management of spasticity in multiple sclerosis. International Journal of MS Care 1999; 1: 16-21.
4. Nance PW. Tizanidine; an alpha2-agonist imidazoline with antispasticity effect. Todays's Therapeutic Trends 1997; 15: 11-25.
5. Wagstaff AJ, Bryson HM. Tizanidine; a review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs 1997; 53: 435-452.
6. Nance PW, Bugaresti J, Shellenberger K, Sheramata W, Martinez- Arizala A, and the North American Tizanidine Study Group. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. Neurology 1994; 44 Suppl 19: S44-S52.
7. Lastate X, Emre M, Davis C, Groves L. Comparative profile of tizanidine in the management of spasticity. Neurology 1994; 44 Suppl 9: S53-59.
8. Georgiev MI. Mechanism of tizanidine action on spasticity. Acta Neurol Scand 1994; 89: 274-279.
9. United Kingdom Tizanidine Trial Group. A double blind placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. Neurology 1994; 44 Suppl 9: S70-78.
10. Wallace JD. Summary of combined clinical analysis of controlled clinical trials with tizanidine. Neurology 1994; 44 Suppl 9: S60-69.
11. Groves L, Shellenberger MK, Davis CS. Tizanidine treatment of spasticity; a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam. Advanced Therapeutics 1998; 15: 241-251.
12. Berry H, Hutchinson DR. Tizanidine and ibuprofen in acute low back pain; results of a double blind multi-center study in general practice. J Int Med Res 1988; 16: 83-91.
13. Koyuncuoglu H. The combination of tizanidine markedly improves the treatment with dextromethorphan of heroin-addicted outpatients. Int J Clin Pharmacol Ther 1995; 33: 13-19.
14. Fogelholm R, Murros K. Tizanidine in chronic tension type headache: a placebo controlled double blind crossover study. Headache 1992; 32: 509-513.
15. Davidoff RA. Antispasticity drugs: mechanisms of action. Ann Neurol 1985; 17: 107-116.
16. Young RR, Delwaide PJ. Drug therapy; spasticity. N Engl J Med 1981; 304: 28-33.
17. Roussan M, Terence C, Fromm G. Baclofen versus diazepam for the treatment of spasticity and long-term follow-up of baclofen therapy. Pharmacotherapeutics 1985; 4: 278-284.
18. Fromm GH. Baclofen as an adjuvant analgesic. J Pain Symptom Manage 1994; 9: 500-509.
19. Ryan DM. Baclofen-induced dyskinesia. Arch Phys Med Rehabil 1993; 74: 766-777.
20. Merritt J. Management of spasticity in spinal cord injury. Mayo Clin Proc 1981; 56: 614-622.
21. Dahlin M, Knutsson E, Nergardh A. Treatment of spasticity on children with low dose benzodiazepine. J Neurol Sci 1993; 117: 54-60.
22. Pinder RM, Brogden RN, Speight TM, Avery GS. Dantrolen sodium a review of its pharmacological properties and therapeutic efficacy in spasticity. Drugs 1997; 13: 3-23.
23. Donovan WH, Carter RE, Ross CD, Wilkinson MA. Clonidine effect on spasticity: a clinical trial. Arch Phys Med Rehabil 1988; 69: 193-194.
24. Priebe MM, Sheerwood AM, Graves DE, Muller M, Olson WH. Effectiveness of gabapentin in controlling spasticity: a quantitative study. Spinal Cord 1997; 35: 171-175.
25. Grant SM, Heel RC. Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties and, therapeutic potential in epilepsy and disorders of motor control. Drugs 1991; 41: 889-926.
26. French JA. Vigabatrin. Epilepsia 1999; 40: S11-S16.
27. Nance P. A comparison of clonidine, cyproheptadine and baclofen in spastic spinal cord injured patients. J Am Paraplegia Soc 1994; 17: 151-157.
28. Zachariah SB, Borges EF, Varghese R, Cruz AR, Ross GS. Positive response to oral divalproex sodium (Depakote) in patient with spasticity and pain. Am J Med Sci 1994; 308: 38-40.
29. Parke B, Penn RD, Savoy SM, Corcos D. Functional outcome after delivery of intrathecal baclofen. Arch Phys Med Rehabil 1989; 7: 30-32.
30. Albright AL, Barron WB, Wasick MP, Polinko P, Janosky J. Continuous intrathecal baclofen infusion for spasticity of cerebral origin. JAMA 1993; 270: 245-277.
31. Coffrey RJ, Cahill D, Strees W, Park TS. Intrathecal baclofen for intractable spasticity of spinal origin: results of long-term multicentre study. J Neurosurg 1993; 78: 226-232.
32. Ochs G, Struppler A, Meyerson BA, Linderoth B, Gybels J. Intrathecal baclofen for long term treatment of spasticity: a multicentre study. J Neurol Neurosurg Psychiatry 1989; 52: 933-939.
33. Meythaler JM, Stress WD, Tuel SM, Cross LL, Haworth CS. Continuous intrathecal baclofen in spinal cord spasticity. Am J Phys Med Rehabil 1992; 71: 321-327.
34. Erickson DL, Blacklock JB, Michaelson M, Sperling KB, Lo JN. Control of spasticity by implantable continuous flow morphine pump. Neurology 1985; 16: 215-217.
35. Hambleton P. Clostridium botulinum toxins; a general review of involvement in disease, structure, mode of action, and preparation for clinical use. J Neurol 1992; 239: 16-20.
36. Grazko MA, Polo JB, Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 1995; 45: 712-717.
37. Simpson DM, Alexander DN, O'Brien CF. Botulinum toxin type A in the treatment of upper extremity spasticity: A randomized double blind placebo-controlled trial. Neurology 1996; 46: 1306-1310.